Hims & Hers Health, Inc. (NYSE:HIMS) CEO Sells $3,943,981.44 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CEO Andrew Dudum sold 188,888 shares of the business’s stock in a transaction that occurred on Tuesday, November 5th. The stock was sold at an average price of $20.88, for a total value of $3,943,981.44. Following the sale, the chief executive officer now directly owns 67,015 shares of the company’s stock, valued at $1,399,273.20. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website.

Andrew Dudum also recently made the following trade(s):

• On Friday, September 20th, Andrew Dudum sold 45,767 shares of Hims & Hers Health stock. The stock was sold at an average price of $16.33, for a total value of $747,375.11.
• On Tuesday, September 3rd, Andrew Dudum sold 188,888 shares of Hims & Hers Health stock. The stock was sold at an average price of $14.56, for a total transaction of $2,750,209.28.

Hims & Hers Health Stock Up 0.9 %

HIMS traded up $0.20 on Thursday, hitting $23.62. The company’s stock had a trading volume of 13,261,955 shares, compared to its average volume of 8,640,148. The firm has a market cap of $5.07 billion, a P/E ratio of 54.80 and a beta of 1.06. The company’s 50 day simple moving average is $18.40 and its 200-day simple moving average is $18.29. Hims & Hers Health, Inc. has a 12 month low of $6.58 and a 12 month high of $25.74.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a return on equity of 11.67% and a net margin of 8.19%. The business had revenue of $401.56 million for the quarter, compared to analysts’ expectations of $382.20 million. During the same quarter in the prior year, the firm posted ($0.04) EPS. The firm’s quarterly revenue was up 77.1% on a year-over-year basis. Equities analysts predict that Hims & Hers Health, Inc. will post 0.22 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on HIMS. Needham & Company LLC began coverage on shares of Hims & Hers Health in a report on Thursday, August 22nd. They set a “buy” rating and a $24.00 price target on the stock. Bank of America boosted their target price on Hims & Hers Health from $23.00 to $25.00 and gave the stock a “buy” rating in a research note on Monday, October 21st. Deutsche Bank Aktiengesellschaft increased their price target on Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a research report on Wednesday. Canaccord Genuity Group boosted their price objective on Hims & Hers Health from $24.00 to $28.00 and gave the stock a “buy” rating in a research report on Tuesday. Finally, Piper Sandler reaffirmed a “neutral” rating and set a $21.00 target price (up from $18.00) on shares of Hims & Hers Health in a research report on Tuesday. Eight research analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company. According to MarketBeat.com, Hims & Hers Health has an average rating of “Moderate Buy” and an average target price of $21.00.

Institutional Trading of Hims & Hers Health

A number of hedge funds and other institutional investors have recently bought and sold shares of HIMS. Nisa Investment Advisors LLC lifted its position in Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after purchasing an additional 1,603 shares during the last quarter. Quest Partners LLC increased its stake in Hims & Hers Health by 5,944.1% in the second quarter. Quest Partners LLC now owns 3,566 shares of the company’s stock valued at $72,000 after acquiring an additional 3,507 shares during the last quarter. CWM LLC lifted its stake in Hims & Hers Health by 21.4% during the third quarter. CWM LLC now owns 5,982 shares of the company’s stock worth $110,000 after purchasing an additional 1,054 shares during the last quarter. Van ECK Associates Corp purchased a new position in shares of Hims & Hers Health in the 2nd quarter worth about $111,000. Finally, Amalgamated Bank increased its position in shares of Hims & Hers Health by 55.9% during the 2nd quarter. Amalgamated Bank now owns 6,566 shares of the company’s stock valued at $133,000 after purchasing an additional 2,354 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.